Bio-Rad’s iQ-Check Salmonella II Real-Time PCR Kit Earns Approval as an AOAC Official Method of Analysis


Date: 10/27/2017

Kit Enables Detection of Salmonella in Raw Meat in 12 Hours or Less

 iQ-Check Salmonella II Real-Time PCR Kit
Bio-Rad’s iQ-Check Salmonella II Real-Time PCR Kit has earned First Action Official Method of Analysis status by AOAC INTERNATIONAL for the detection of Salmonella spp. in raw meat in as few as 12 hours.

HERCULES, Calif. — October 27, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced that the AOAC INTERNATIONAL validated its iQ-Check® Salmonella II Real-Time PCR Kit as a First Action Official Method of Analysis (OMA method number 2017.06) for the detection of Salmonella raw meat in as little as 12 hours and as little as 20 hours for all other samples, including food and environmental surfaces.

The Official Methods of Analysis (OMA) program is AOAC INTERNATIONAL’s premier program for evaluating analytical methods in chemistry, microbiology, and molecular biology. Methods undergo rigorous scientific scrutiny, and only those demonstrating the highest level of confidence are granted Official Method approval.

To earn this designation, Bio-Rad conducted a collaborative study evaluating the reproducibility and performance of the iQ-Check Salmonella II Real-Time PCR Kit. Dry pet food and milk chocolate were selected for evaluation, as they are especially challenging matrices due to the large presence of inhibitory compounds.

“This is a significant validation that puts the iQ-Check Salmonella II Real-Time PCR method at the level of an official method,” said Jean-François Chauvet, Bio-Rad Vice President and General Manager, Food Science Division. “The OMA program is designed to identify the most reliable methods, ensuring that investigators in a wide range of industrial applications can use them to test with confidence. By selecting challenging matrices with large sample sizes for this validation, we have demonstrated the robustness of the method.”

This AOAC validation approves the iQ-Check Salmonella II Real-Time PCR Kit for a variety of food and environmental surfaces, including: 375 g test portions of raw ground chicken, ready-to-eat deli ham, dry dog food, wet cat food, milk chocolate, raw milk cheese, 30 ml chicken carcass rinse, 25 g test portions of whole eggs, raw ground beef, raw ground chicken, cantaloupe, peanut butter, raw chicken breast, raw pork, and fresh spinach. Validated surfaces include stainless steel, ceramic, plastic, and sealed concrete.

The iQ-Check Salmonella II PCR Detection Kit is based on the fast, sensitive, and proven technology of real-time PCR. Due to the sensitivity and specificity of PCR, results can be obtained in as little as 12 hours for raw meat samples and in 20 hours for all other samples (including food and environmental samples) following a single enrichment in a nonselective medium.

The iQ-Check Free DNA Removal Solution protocol is also included under the scope of the AOAC validation. This method provides an ideal way to remove free DNA from food and environmental samples prior to PCR analysis without the need for hazardous reagents such as ethidium or propidium monoazide.

Please visit for more information on the iQ-Check Salmonella II Real-Time PCR Kit.

Bio-Rad and iQ-Check are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,350 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “can,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact:
Bio-Rad Laboratories, Inc.
Wendy Lauer

CG Life
Ken Li

Sign Up for Bio-Rad Updates!
Enter your email address below to receive your choice of the latest news, promotions, and more.
Get Help